Seres Therapeutics, Inc. (MCRB) Stock

Seres Therapeutics, Inc. operates as a leading microbiome therapeutics platform company, focusing on the development of bacterial consortia designed to interact functionally with host cells and tissues to combat disease. At the forefront of its innovative pipeline is SER-109, an oral microbiome therapeutic that has successfully completed Phase III clinical trials for the treatment of clostridium difficile infection (CDI). The company also advances SER-155, a cultivated bacteria microbiome drug currently in Phase Ib trials aimed at reducing gastrointestinal and bloodstream infections, as well as graft versus host disease in immunocompromised patients undergoing stem cell and solid organ transplants.

In addition to these pioneering treatments, Seres Therapeutics is actively developing SER-287 and SER-301 in Phase Ib trials for the treatment of ulcerative colitis, along with SER-401 targeting metastatic melanoma patients, and SER-262 designed to address Clostridioides difficile infection. These initiatives underscore the company's commitment to leveraging microbiome science to address a wide range of challenging medical conditions.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Seres Therapeutics has established strategic license and collaboration agreements with partners such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. These partnerships bolster the company's research and development efforts, facilitating the advancement of innovative therapies that harness the potential of the microbiome to improve patient outcomes globally.

Formerly known as Seres Health, Inc., the company rebranded to Seres Therapeutics, Inc. in May 2015 to reflect its expanded focus and commitment to advancing microbiome-based therapies. With a robust pipeline and a pioneering spirit, Seres Therapeutics continues to lead the way in microbiome research and development, striving to transform the treatment landscape for patients in need of innovative therapeutic solutions.